Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study-Reference-Cited by-同舟云学术

Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study

Published:2021-06-21 Issue:1 Volume:189 Page:167-175
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Kim Haeyoung^ORCID,Kim Yeon Jeong,Park Donghyun,Park Woong-Yang,Choi Doo Ho,Park Won,Cho Won kyung,Kim Nalee

Funder

Ministry of Science and ICT, Korea

Samsung Medical Center, Korea

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06296-3.pdf

Reference36 articles.

1. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted Therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485–1505. https://doi.org/10.1200/JCO.20.03399

2. Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, El-Tamer M, Gemignani ML, Heerdt AS, Sclafani LM, Sacchini V, Cody HS 3rd, Patil S, Morrow M (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 23:3467–3474. https://doi.org/10.1245/s10434-016-5246-8

3. Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR (2015) Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg 220:1063–1069. https://doi.org/10.1016/j.jamcollsurg.2015.02.011

4. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147–2159. https://doi.org/10.1056/NEJMoa1612645

5. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wulfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, Investigators K (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617–628. https://doi.org/10.1056/NEJMoa1814017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research History, Current Trends, and Future Prospects of Liquid Biopsy in Triple-Negative Breast Cancer: An Analysis from a Global Perspective;2024-04-05

2. Liquid Biopsy: Insights Into Monitoring Tumor Dynamics and Response to Therapy in Patients with Breast Cancer;The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach;2023-12-18

3. Implication of Pre- and Post-Radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study;Cancer Research and Treatment;2023-11-10

4. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study;eLife;2023-11-06

5. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment;Cancer Medicine;2023-09-25